Posted by Michael Wonder on 11 Mar 2019
NICE provisionally approves Almirall's Ilumetri (tildrakizumab), as a cost effective option for adults with moderate-to-severe plaque psoriasis
8 March 2019 - Final NICE approval is expected in April 2019.
Almirall announced today that the NICE has provisionally recommended approval of Ilumetri (tildrakizumab), a humanised, high-affinity IL-23p19 monoclonal antibody, for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
Following a single health technology assessment submission to NICE in August 2018 and the subsequent questions for clarification and appraisal committee meetings, NICE completed their assessment of tildrakizumab and has now issued a Final Appraisal Determination (FAD) provisionally recommending tildrakizumab as a cost effective treatment option for the NHS for the patients specified in the FAD.
